Liquidia reports YUTREPIA sales growth, begins enrollment in L606 pivotal study

Liquidia Corporation reported second quarter 2026 results on August 12, 2026, disclosing that the company has begun site activation and enrollment in Re-Spire, its pivotal study for L606, which CEO Roger Jeffs said the company believes can extend the tolerability and dosing advantages established by YUTREPIA.¹ L606 is described as an investigational, extended-release formulation of treprostinil administered twice-daily with a next-generation nebulizer that uses a proprietary liposomal formulation to release the drug slowly and at a controlled rate into the lung.¹ The company said L606 is also being studied in an open-label trial in the United States for PAH and PH-ILD, in addition to the global, placebo-controlled Re-Spire study focused on PH-ILD.¹

On the commercial side, YUTREPIA net product sales reached approximately $170.4 million in the quarter, up 31% from the first quarter of 2026.¹ The company said it has now received about 5,900 unique patient prescriptions and started more than 5,000 patients on treatment since the June 2025 launch, with prescription-to-start conversion remaining above 85%.¹ The prescriber base has also grown, with more than 1,100 total prescribers to date, over 30% of whom have prescribed YUTREPIA to at least five patients.¹

Financially, Liquidia posted its fourth consecutive quarter of increasing profitability, reporting net income of $74.7 million and adjusted EBITDA of $96.3 million, alongside a $61.4 million increase in cash and cash equivalents compared to the first quarter of 2026.¹ Cash and cash equivalents totaled $284.2 million as of June 30, 2026, up from $190.7 million at the end of 2025.¹ The company also noted it is advancing ten clinical studies supporting YUTREPIA and L606 across existing and potential new indications.¹